Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 14, 2021

SELL
$11.34 - $21.37 $134,503 - $253,469
-11,861 Closed
0 $0
Q2 2021

Jul 20, 2021

SELL
$19.4 - $28.71 $182,204 - $269,644
-9,392 Reduced 44.19%
11,861 $251,000
Q1 2021

May 05, 2021

SELL
$25.12 - $36.89 $626,191 - $919,593
-24,928 Reduced 53.98%
21,253 $596,000
Q1 2020

Apr 27, 2020

SELL
$27.44 - $73.84 $182,338 - $490,666
-6,645 Reduced 12.58%
46,181 $1.46 Million
Q1 2019

Apr 22, 2019

BUY
$40.11 - $53.57 $1.25 Million - $1.67 Million
31,264 Added 145.0%
52,826 $2.12 Million
Q2 2018

Jul 31, 2018

SELL
$36.2 - $76.4 $362,000 - $764,000
-10,000 Reduced 31.68%
21,562 $1,000
Q1 2018

May 03, 2018

SELL
$65.94 - $80.76 $5.52 Million - $6.77 Million
-83,782 Reduced 72.64%
31,562 $2,000
Q4 2017

Jan 17, 2018

BUY
$43.47 - $67.43 $5.01 Million - $7.78 Million
115,344
115,344 $7.59 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $155M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Hamilton Lane Advisors LLC Portfolio

Follow Hamilton Lane Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hamilton Lane Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hamilton Lane Advisors LLC with notifications on news.